Quest Diagnostics Inc. closed 8.75% short of its 52-week high of $182.38, which the company achieved on June 16th.

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

This was the stock's second consecutive day of losses.

Quest Diagnostics (DGX) is a strong buy with growth potential, solid margins, and dividend increases. Discover the full ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is ...

The Durham-based parent company says it still plans to grow Q2 Solutions’ local headcount despite the grant terminations.

Substance use occurs more often in blue-collar and service industry jobs, but comprehensive policies and supportive ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Before the New York Giants reach training camp, Jaxson Dart was on vacation and showing off his arm strength in a new viral ...